Prostate Cancer

Description

The prostate is the gland below a man's bladder that produces fluid for semen. Prostate cancer is common among older men. It is rare in men younger than 40. Risk factors for developing prostate cancer include being over 65 years of age, family history, and being African-American. Symptoms of prostate cancer may include Problems passing urine, such as pain, difficulty starting or stopping the stream, or dribbling Low back pain Pain with ejaculation To diagnose prostate cancer, you doctor may do a digital rectal exam to feel the prostate for lumps or anything unusual. You may also get a blood test for prostate-specific antigen (PSA). These tests are also used in prostate cancer screening, which looks for cancer before you have symptoms. If your results are abnormal, you may need more tests, such as an ultrasound, MRI, or biopsy. Treatment often depends on the stage of the cancer. How fast the cancer grows and how different it is from surrounding tissue helps determine the stage. Men with prostate cancer have many treatment options. The treatment that's best for one man may not be best for another. The options include watchful waiting, surgery, radiation therapy, hormone therapy, and chemotherapy. You may have a combination of treatments. NIH: National Cancer Institute

Clinical Features

Phenotypes and symptoms related to Prostate Cancer

  • Neoplasm
  • Carcinoma
  • Neoplasm of the skin
  • Breast carcinoma
  • Neoplasm of the lung
  • Prostate cancer

Incidence and onset information

— Currently we don't have prevalence information about this disease (Not enough data available about incidence and published cases.)
No data available about the known clinical features onset.

Researches and researchers

Currently, we don't have any information about doctors, researches or researchers related to this disease. Please contact us if you would like to appear here.

Prostate Cancer Recommended genes panels

Panel Name, Specifity and genes Tested/covered
Hereditary High Risk Breast Cancer Panel.

By Baylor Miraca Genetics Laboratories (United States).

BRCA1, BRCA2, STK11, TP53, CDH1, PALB2, PTEN
Specificity
43 %
Genes
30 %
Hereditary High Risk Breast Cancer Panel.

By Baylor Miraca Genetics Laboratories (United States).

BRCA1, BRCA2, STK11, TP53, CDH1, PALB2, PTEN
Specificity
43 %
Genes
30 %
Comprehensive Hereditary Cancer Panel.

By Baylor Miraca Genetics Laboratories (United States).

RUNX1, SDHA, SDHB, SDHC, SDHD, BMPR1A, BRCA1, BRCA2, STK11, EPCAM, TP53, VHL, WT1, CBL, SUFU, CDC73, CDH1, CDK4, CDKN1C, CDKN2A , (...)

View the complete list with 39 more genes
Specificity
6 %
Genes
30 %
Hereditary Colorectal/Gastrointestinal Cancer Panel.

By Baylor Miraca Genetics Laboratories (United States).

BMPR1A, BRCA1, BRCA2, STK11, EPCAM, TP53, CDH1, CDK4, CDKN2A, PALB2, ENG, APC, SMAD4, MLH1, MSH2, MSH6, MUTYH, ATM, PMS1, PMS2 , (...)

View the complete list with 1 more genes
Specificity
15 %
Genes
30 %
Comprehensive breast and ovarian cancer panel testing (18 genes).

By Molecular Genetics Laboratory Centro de Investigaciones Endocrinologicas "Dr. Cesar Bergada" (Argentina).

BRCA1, BRCA2, STK11, EPCAM, TP53, CDH1, BRIP1, PALB2, MLH1, MSH2, MSH6, MUTYH, ATM, PMS2, PTEN, RAD51C, RAD51D
Specificity
18 %
Genes
30 %
Comprehensive breast cancer panel testing (10 genes).

By Molecular Genetics Laboratory Centro de Investigaciones Endocrinologicas "Dr. Cesar Bergada" (Argentina).

BRCA1, BRCA2, STK11, TP53, CDH1, BRIP1, PALB2, ATM, PTEN
Specificity
34 %
Genes
30 %
Hereditary Diffuse Gastric Cancer.

By DNA Diagnostic Laboratory Henry Ford Hospital (United States).

CDH1
Specificity
100 %
Genes
10 %
CDH1 full gene sequencing analysis.

By Clinical Molecular Diagnostic Laboratory City of Hope National Medical Center (United States).

CDH1
Specificity
100 %
Genes
10 %

You can get up to 788 more panels with our dedicated tool

Learn more

Sources and references

You can check the following sources for additional information.

OMIM Genetic Syndrome Finder

If you liked this article maybe you will also find interesting the following in-depth articles about other rare diseases, like MICROCEPHALY-MICROMELIA SYNDROME; MIMIS BLOOD GROUP, VEL SYSTEM; VEL SHPRINTZEN-GOLDBERG CRANIOSYNOSTOSIS SYNDROME; SGS EHLERS-DANLOS SYNDROME, HYPERMOBILITY TYPE CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIa; CDG2A CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIo; CDG2O